Effect of CGS-8216 on high-dose flurazepam convulsive threshold.
Flurazepam, a clinically proven and widely accepted sedative hypnotic, has been shown by a number of investigators to produce convulsions at toxic doses. In the present study, CGS-8216, a benzodiazepine receptor antagonist, reduced the dose of flurazepam required to produce convulsions. This suggests that the convulsant action of FLZ is exerted at a site other than the benzodiazepine receptor.
D000818:Animals; D001569:Benzodiazepines / Q000037:antagonists & inhibitors*; D003292:Convulsants / Q000494:pharmacology*; D004305:Dose-Response Relationship, Drug; D005479:Flurazepam / Q000494:pharmacology*; D008297:Male; D011720:Pyrazoles / Q000494:pharmacology*; D051381:Rats; D011919:Rats, Inbred Strains; D011963:Receptors, GABA-A / Q000187:drug effects
D003292:Convulsants; D011720:Pyrazoles; D011963:Receptors, GABA-A; D001569:Benzodiazepines; C033830:2-phenylpyrazolo(4,3-c)quinolin-3(5H)-one; D005479:Flurazepam